TickerStat.comEloxx Pharmaceuticals annual total liabilities
2011
2012
2013
2014
2015
2015
2016
2016
2017
2017
2018
2019
2020
2021
2022
2023
2024
2025
Eloxx Pharmaceuticals Total Liabilities Growth & History (ELOX)
Eloxx Pharmaceuticals's total liabilities was $17.2M for fiscal 2025.
View full Eloxx Pharmaceuticals company overviewEloxx Pharmaceuticals annual total liabilities history
| Fiscal year | Period ended | Total liabilities | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $17.2M | −$10.1M | −37.11% |
| 2024 | 2024-12-31 | $27.3M | $3.0M | +12.34% |
| 2023 | 2023-12-31 | $24.3M | −$7.5M | −23.51% |
| 2022 | 2022-12-31 | $31.8M | $9.0M | +39.67% |
| 2021 | 2021-12-31 | $22.8M | $6.5M | +40.06% |
| 2020 | 2020-12-31 | $16.2M | −$6.5M | −28.53% |
| 2019 | 2019-12-31 | $22.7M | $14.9M | +191.20% |
| 2018 | 2018-12-31 | $7.8M | $4.4M | +128.07% |
| 2017 · Dec 31 | 2017-12-31 | $3.4M | $458,802 | +15.48% |
| 2017 · Jun 30 | 2017-06-30 | $5.0M | $308,700 | +6.62% |
| 2016 · Dec 31 | 2016-12-31 | $3.0M | −$4.0M | −57.16% |
| 2016 · Jun 30 | 2016-06-30 | $4.7M | −$2.7M | −36.29% |
| 2015 · Dec 31 | 2015-12-31 | $6.9M | — | — |
| 2015 · Jun 30 | 2015-06-30 | $7.3M | $1.5M | +25.28% |
| 2014 | 2014-06-30 | $5.8M | $2.5M | +76.49% |
| 2013 | 2013-06-30 | $3.3M | −$190,171 | −5.43% |
| 2012 | 2012-06-30 | $3.5M | −$577,585 | −14.16% |
| 2011 | 2011-06-30 | $4.1M | — | — |
Eloxx Pharmaceuticals quarterly total liabilities
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q4.15
Q1.16
Q4.16
Q1.17
Q4.16
Q1.17
Q4.17
Q1.18
Q4.17
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q4.24
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total liabilities | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $17.0M | — | — |
| Q1 2026 | 2026-03-31 | $16.1M | — | — |
| Q4 2025 | 2025-12-31 | $17.2M | −$10.1M | −37.11% |
| Q4 2024 | 2024-12-31 | $27.3M | $3.0M | +12.34% |
| Q4 2023 | 2023-12-31 | $24.3M | −$7.5M | −23.51% |
| Q3 2023 | 2023-09-30 | $26.1M | −$5.8M | −18.11% |
| Q2 2023 | 2023-06-30 | $24.6M | −$6.5M | −21.01% |
| Q1 2023 | 2023-03-31 | $23.5M | −$8.4M | −26.43% |
| Q4 2022 | 2022-12-31 | $31.8M | $9.0M | +39.67% |
| Q3 2022 | 2022-09-30 | $31.9M | $9.5M | +42.33% |
| Q2 2022 | 2022-06-30 | $31.1M | $11.2M | +55.90% |
| Q1 2022 | 2022-03-31 | $31.9M | $14.3M | +81.27% |
| Q4 2021 | 2021-12-31 | $22.8M | $6.5M | +40.06% |
| Q3 2021 | 2021-09-30 | $22.4M | $4.5M | +25.31% |
| Q2 2021 | 2021-06-30 | $20.0M | $337,000 | +1.72% |
| Q1 2021 | 2021-03-31 | $17.6M | −$3.2M | −15.24% |
| Q4 2020 | 2020-12-31 | $16.2M | −$6.5M | −28.53% |
| Q3 2020 | 2020-09-30 | $17.9M | −$5.0M | −21.75% |
| Q2 2020 | 2020-06-30 | $19.6M | −$4.2M | −17.57% |
| Q1 2020 | 2020-03-31 | $20.8M | −$1.7M | −7.45% |
| Q4 2019 | 2019-12-31 | $22.7M | $14.9M | +191.20% |
| Q3 2019 | 2019-09-30 | $22.8M | $17.8M | +349.48% |
| Q2 2019 | 2019-06-30 | $23.8M | $19.5M | +446.72% |
| Q1 2019 | 2019-03-31 | $22.5M | — | — |
| Q4 2018 | 2018-12-31 | $7.8M | $4.4M | +128.07% |
| Q3 2018 | 2018-09-30 | $5.1M | $1.8M | +55.02% |
| Q2 2018 | 2018-06-30 | $4.4M | −$617,994 | −12.42% |
| Q4 2017 · Dec 31 | 2017-12-31 | $3.4M | $458,802 | +15.48% |
| Q1 2018 · Sep 30 | 2017-09-30 | $3.3M | −$110,527 | −3.26% |
| Q4 2017 · Jun 30 | 2017-06-30 | $5.0M | $308,700 | +6.62% |
| Q1 2017 · Mar 31 | 2017-03-31 | $3.3M | −$1.7M | −33.76% |
| Q4 2016 · Dec 31 | 2016-12-31 | $3.0M | −$4.0M | −57.16% |
| Q1 2017 · Sep 30 | 2016-09-30 | $3.4M | −$3.5M | −51.16% |
| Q4 2016 · Jun 30 | 2016-06-30 | $4.7M | −$2.7M | −36.29% |
| Q1 2016 · Mar 31 | 2016-03-31 | $4.9M | −$796,088 | −13.93% |
| Q4 2015 · Dec 31 | 2015-12-31 | $6.9M | $305,165 | +4.61% |
| Q1 2016 · Sep 30 | 2015-09-30 | $6.9M | $1.2M | +21.51% |
| Q4 2015 · Jun 30 | 2015-06-30 | $7.3M | $1.5M | +25.28% |
| Q3 2015 | 2015-03-31 | $5.7M | $4.6M | +394.68% |
| Q2 2015 | 2014-12-31 | $6.6M | $3.2M | +95.61% |
| Q1 2015 | 2014-09-30 | $5.7M | $2.0M | +54.35% |
| Q4 2014 | 2014-06-30 | $5.8M | $2.5M | +76.49% |
| Q3 2014 | 2014-03-31 | $1.2M | −$2.4M | −67.74% |
| Q2 2014 | 2013-12-31 | $3.4M | −$501,471 | −12.92% |
| Q1 2014 | 2013-09-30 | $3.7M | $66,685 | +1.84% |
| Q4 2013 | 2013-06-30 | $3.3M | −$190,171 | −5.43% |
| Q3 2013 | 2013-03-31 | $3.6M | −$455,471 | −11.29% |
| Q2 2013 | 2012-12-31 | $3.9M | −$141,031 | −3.50% |
| Q1 2013 | 2012-09-30 | $3.6M | −$707,839 | −16.32% |
| Q4 2012 | 2012-06-30 | $3.5M | −$577,585 | −14.16% |
| Q3 2012 | 2012-03-31 | $4.0M | — | — |
| Q2 2012 | 2011-12-31 | $4.0M | — | — |
| Q1 2012 | 2011-09-30 | $4.3M | — | — |
| Q4 2011 | 2011-06-30 | $4.1M | — | — |
Eloxx Pharmaceuticals total liabilities trends
Over the last five fiscal years, Eloxx Pharmaceuticals's total liabilities increased from $16.2M to $17.2M, a change of $930,000. The latest reported quarter, Q2 2026, shows $17.0M.
About the metric
What total liabilities mean
Total liabilities are all obligations reported on a company’s balance sheet, including debt, accounts payable, accrued expenses, deferred revenue, lease liabilities, and other current and long-term obligations.
Calculation and source
SEC-reported and calculated total liabilities
TickerStat uses total liabilities reported in company SEC filings when available. Otherwise, it calculates total liabilities as aligned total assets minus total equity for the same balance-sheet date. Total liabilities should not be confused with interest-bearing debt. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Eloxx Pharmaceuticals source filings ↗Community posts
Eloxx doses first patients in mid-stage Alport syndrome trial
Eloxx Pharmaceuticals ($ELOX) dosed the first two patients in its Phase 2b EXACT study of exaluren for Alport syndrome caused by nonsense mutations. The trial plans to enroll 24 patients with relevant mutations in the COL4A3, COL4A4 or COL4 ...